Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Current Deferred Revenue: 2021-2024

Historic Current Deferred Revenue for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $31,448.

  • ProQR Therapeutics N.V's Current Deferred Revenue fell 16.42% to $28,203 in Q3 2025 from the same period last year, while for Sep 2025 it was $28,203, marking a year-over-year decrease of 16.42%. This contributed to the annual value of $31,448 for FY2024, which is 34.18% down from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Current Deferred Revenue of $31,448 as of FY2024, which was down 34.18% from $47,779 recorded in FY2023.
  • ProQR Therapeutics N.V's 5-year Current Deferred Revenue high stood at $6.1 million for FY2021, and its period low was $31,448 during FY2024.
  • In the last 3 years, ProQR Therapeutics N.V's Current Deferred Revenue had a median value of $47,779 in 2023 and averaged $1.9 million.
  • Data for ProQR Therapeutics N.V's Current Deferred Revenue shows a maximum YoY slumped of 99.17% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows ProQR Therapeutics N.V's Current Deferred Revenue stood at $6.1 million in 2021, then declined by 4.92% to $5.8 million in 2022, then crashed by 99.17% to $47,779 in 2023, then slumped by 34.18% to $31,448 in 2024.